Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Intrinsic Value
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. [ Read More ]
The intrinsic value of one
AUPH
stock under the Base Case scenario is
14.35
USD.
Compared to the current market price of 5.05 USD,
Aurinia Pharmaceuticals Inc
is
Undervalued by 65%.
Aurinia Pharmaceuticals Inc's market capitalization is 726.4m USD.
AUPH stock price is 5.05 USD.
AUPH stock price (5.05 USD) is 65% less than its Intrinsic Value (14.35 USD).
AUPH has upside potential of 128% compared to the average analyst price target.
Open Wall St Estimates
AUPH's Revenue has grown by an exceptional 31% over the past 12 months.
AUPH's ROE (Return on Equity) has significantly increased in the last 3 years from -39% to -20%, and is approaching profitability.
AUPH's Revenue is forecast to grow at a rate of 29% per year over the next 3 years.
AUPH's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -317% to -70%, and is approaching profitability.
AUPH's Altman Z-Score is equal to 1.92.
AUPH's ROE (Return on Equity) for the past 12 months is negative and is equal to -20%.
AUPH has negative Operating Income for the last twelve months.
AUPH has negative Net Income for the last twelve months.
AUPH's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -70%.
AUPH has positive Gross Profit for the last twelve months.
AUPH's Revenue has been growing by an exceptional 52% per year for the last 3 years.
AUPH has negative Free Cash Flow for the last twelve months.
AUPH's long-term assets (548m USD) exceed its long-term liabilties (170m USD).
AUPH's D/E (Debt to Equity) is very low and is equal to 0.2.
AUPH has negative three-year average ROE (Return on Equity): -33%. The company is not efficient at transforming stockholders' equity into net income.
AUPH has negative three-year average ROIC (Return on Invested Capital): -212%. The company is not efficient at using invested capital to generate operating income.
AUPH's short-term assets (425m USD) exceed its short-term liabilties (77m USD).
AUPH has negative Net Debt. This means that the company has more cash and short-term investments (350m USD) than debt (75m USD).
Valuation Backtest
Aurinia Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
AUPH
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Aurinia Pharmaceuticals Inc
Balance Sheet Decomposition
Aurinia Pharmaceuticals Inc
| Current Assets | 424.8m |
| Cash & Short-Term Investments | 350.4m |
| Receivables | 24.1m |
| Other Current Assets | 50.3m |
| Non-Current Assets | 123.3m |
| Long-Term Investments | 201k |
| PP&E | 116.6m |
| Intangibles | 5m |
| Other Non-Current Assets | 1.5m |
| Current Liabilities | 77.2m |
| Accounts Payable | 4.3m |
| Accrued Liabilities | 50.4m |
| Other Current Liabilities | 22.5m |
| Non-Current Liabilities | 92.9m |
| Long-Term Debt | 75.5m |
| Other Non-Current Liabilities | 17.4m |
Earnings Waterfall
Aurinia Pharmaceuticals Inc
|
Revenue
|
175.5m
USD
|
|
Cost of Revenue
|
-14.1m
USD
|
|
Gross Profit
|
161.4m
USD
|
|
Operating Expenses
|
-253.1m
USD
|
|
Operating Income
|
-91.7m
USD
|
|
Other Expenses
|
13.7m
USD
|
|
Net Income
|
-78m
USD
|
Free Cash Flow Analysis
Aurinia Pharmaceuticals Inc
What is Free Cash Flow?
AUPH Profitability Score
Profitability Due Diligence
Aurinia Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Aurinia Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
AUPH Solvency Score
Solvency Due Diligence
Aurinia Pharmaceuticals Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Aurinia Pharmaceuticals Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AUPH Price Targets Summary
Aurinia Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
AUPH
is 11.51 USD
with a low forecast of 8.08 USD and a high forecast of 15.75 USD.
Ownership
AUPH Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AUPH Price
Aurinia Pharmaceuticals Inc
| Average Annual Return | 48.78% |
| Standard Deviation of Annual Returns | 140.25% |
| Max Drawdown | -88% |
| Market Capitalization | 726.4m USD |
| Shares Outstanding | 144 620 000 |
| Percentage of Shares Shorted | 8.49% |
AUPH News
Last Important Events
Aurinia Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Aurinia Pharmaceuticals Inc
Company Profile
Aurinia Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia and currently employs 300 full-time employees. The company went IPO on 2001-07-16. The firm is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The firm has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The company also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.
Contact
IPO
Employees
Officers
The intrinsic value of one
AUPH
stock under the Base Case scenario is
14.35
USD.
Compared to the current market price of 5.05 USD,
Aurinia Pharmaceuticals Inc
is
Undervalued by 65%.
You don't have any saved screeners yet
